JP2024023228A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023228A5 JP2024023228A5 JP2023188623A JP2023188623A JP2024023228A5 JP 2024023228 A5 JP2024023228 A5 JP 2024023228A5 JP 2023188623 A JP2023188623 A JP 2023188623A JP 2023188623 A JP2023188623 A JP 2023188623A JP 2024023228 A5 JP2024023228 A5 JP 2024023228A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- molecule
- hla
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762506674P | 2017-05-16 | 2017-05-16 | |
| US62/506,674 | 2017-05-16 | ||
| JP2019563546A JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
| PCT/US2018/032996 WO2018213467A1 (en) | 2017-05-16 | 2018-05-16 | Manabodies and methods of using |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Division JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024023228A JP2024023228A (ja) | 2024-02-21 |
| JP2024023228A5 true JP2024023228A5 (https=) | 2024-08-01 |
| JP7701079B2 JP7701079B2 (ja) | 2025-07-01 |
Family
ID=64274676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Active JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
| JP2023188623A Active JP7701079B2 (ja) | 2017-05-16 | 2023-11-02 | Ｍａｎａボディおよび使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563546A Active JP7381345B2 (ja) | 2017-05-16 | 2018-05-16 | Ｍａｎａボディおよび使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11807662B2 (https=) |
| EP (2) | EP3635000A4 (https=) |
| JP (2) | JP7381345B2 (https=) |
| CN (1) | CN111406068A (https=) |
| AU (2) | AU2018269370B2 (https=) |
| CA (1) | CA3063905A1 (https=) |
| WO (1) | WO2018213467A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018269370B2 (en) | 2017-05-16 | 2025-06-05 | The Johns Hopkins University | Manabodies and methods of using |
| EP3683229A1 (en) * | 2019-01-21 | 2020-07-22 | Charité - Universitätsmedizin Berlin | Specific t cell receptors against epitopes of mutant myd88l265p protein for adoptive t cell therapy |
| CN114026116A (zh) | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL266728B (en) * | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
| WO2021098822A1 (zh) * | 2019-11-21 | 2021-05-27 | 江苏恒瑞医药股份有限公司 | 一种双特异性抗体 |
| WO2021127184A1 (en) * | 2019-12-17 | 2021-06-24 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| IL297697A (en) * | 2020-06-17 | 2022-12-01 | Tiziana Life Sciences Plc | Preparations and methods for improving chimeric antigen receptor t cell therapies |
| EP4255482A1 (en) * | 2020-12-01 | 2023-10-11 | The Johns Hopkins University | Methods and materials for treating t cell cancers |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| CN116574748B (zh) * | 2023-07-10 | 2023-09-12 | 昆明医科大学 | 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法 |
| WO2025106598A1 (en) * | 2023-11-13 | 2025-05-22 | Clasp Therapeutics, Inc. | Modified mana-tces targeting tumor antigens and engaging t cell receptors, and methods of using thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| US6630584B1 (en) | 2000-03-16 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Single chain antibody against mutant p53 |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| JP3738308B2 (ja) | 2002-11-29 | 2006-01-25 | 篤 村口 | 抗原特異的リンパ球抗原受容体遺伝子のクローニング方法 |
| KR20130065723A (ko) | 2003-06-27 | 2013-06-19 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
| WO2005099361A2 (en) | 2003-07-10 | 2005-10-27 | Vaccinex, Inc. | MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN |
| EP1712620A4 (en) * | 2004-01-23 | 2008-05-28 | Greenpeptide Co Ltd | EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR-ORGANIC PEPTIDE |
| AU2005247950B2 (en) | 2004-05-27 | 2012-02-02 | Receptor Logic, Inc. | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| CA2569509C (en) | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| CN101228187A (zh) | 2005-03-25 | 2008-07-23 | 特拉维夫大学拉莫特有限公司 | 针对突变p53的共同表位的人合成单链抗体及其用途 |
| WO2006100681A2 (en) | 2005-03-25 | 2006-09-28 | Ramot At Tel Aviv University Ltd. | Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses |
| CN101309703A (zh) | 2005-09-12 | 2008-11-19 | 诺维莫尼公司 | 抗cd3抗体组合物 |
| RU2008129827A (ru) | 2005-12-21 | 2010-01-27 | МЕДИММЬЮН, ЭлЭлСи (US) | МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ |
| EP2673300B1 (en) | 2011-02-11 | 2016-08-24 | Memorial Sloan-Kettering Cancer Center | Hla-restricted, peptide-specific antigen binding proteins |
| KR102060389B1 (ko) | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| HUE033245T2 (hu) * | 2011-12-19 | 2017-11-28 | Synimmune Gmbh | Bispecifikus ellenanyag molekula |
| CN113684185A (zh) | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| CN106795221B (zh) | 2014-04-03 | 2022-06-07 | 塞勒克提斯公司 | 用于癌症免疫治疗的cd33特异性嵌合抗原受体 |
| US9611325B2 (en) | 2014-07-21 | 2017-04-04 | Wuhan Yzy Biopharma Co., Ltd. | Construction and application of bispecific antibody HER2xCD3 |
| CN118994363A (zh) * | 2014-11-26 | 2024-11-22 | 美国卫生和人力服务部 | 抗突变的kras的t细胞受体 |
| WO2016154047A2 (en) * | 2015-03-20 | 2016-09-29 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
| WO2016154246A1 (en) | 2015-03-23 | 2016-09-29 | The Johns Hopkins University | Hla-restricted epitopes encoded by somatically mutated genes |
| WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| IL294183B2 (en) * | 2015-05-20 | 2023-10-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| NL2014935B1 (en) * | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| AU2016274767B2 (en) * | 2015-06-09 | 2022-05-19 | Eureka Therapeutics, Inc. | T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA |
| GB201513921D0 (en) * | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| ES2879287T3 (es) * | 2015-09-15 | 2021-11-22 | Us Health | Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8 |
| EA201891753A1 (ru) | 2016-02-03 | 2019-01-31 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки |
| IL313507A (en) | 2016-02-03 | 2024-08-01 | Amgen Res Munich Gmbh | Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof |
| CN109843929B (zh) * | 2016-08-23 | 2024-07-05 | 加利福尼亚大学董事会 | 蛋白水解可切割的嵌合多肽及其使用方法 |
| WO2018071796A2 (en) | 2016-10-13 | 2018-04-19 | The Johns Hopkins University | Compositions and methods for identifying functional anti-tumor t cell responses |
| US20200325244A1 (en) * | 2020-05-18 | 2020-10-15 | Abexxa Biologics, Inc. | Antibodies and methods of use thereof |
| AU2018269370B2 (en) | 2017-05-16 | 2025-06-05 | The Johns Hopkins University | Manabodies and methods of using |
| SG11202002635RA (en) | 2017-09-29 | 2020-04-29 | The United States Of America As Represented By The Secretary | Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation |
| CR20200287A (es) * | 2017-12-04 | 2020-11-11 | Us Health | Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado |
| WO2021127184A1 (en) | 2019-12-17 | 2021-06-24 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| WO2021127814A1 (zh) | 2019-12-23 | 2021-07-01 | 深圳市人民医院 | 用于癌症治疗的光纳米疫苗及其制备方法和应用 |
-
2018
- 2018-05-16 AU AU2018269370A patent/AU2018269370B2/en active Active
- 2018-05-16 EP EP18802867.4A patent/EP3635000A4/en not_active Withdrawn
- 2018-05-16 EP EP25190769.7A patent/EP4644427A3/en active Pending
- 2018-05-16 CN CN201880047554.3A patent/CN111406068A/zh active Pending
- 2018-05-16 CA CA3063905A patent/CA3063905A1/en active Pending
- 2018-05-16 US US16/614,005 patent/US11807662B2/en active Active
- 2018-05-16 JP JP2019563546A patent/JP7381345B2/ja active Active
- 2018-05-16 WO PCT/US2018/032996 patent/WO2018213467A1/en not_active Ceased
-
2023
- 2023-09-25 US US18/473,695 patent/US20240294648A1/en active Pending
- 2023-11-02 JP JP2023188623A patent/JP7701079B2/ja active Active
-
2025
- 2025-05-21 AU AU2025203767A patent/AU2025203767A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023228A5 (https=) | ||
| JP2023507729A5 (https=) | ||
| JP2025065142A5 (https=) | ||
| JP2022109953A5 (https=) | ||
| JP2023518134A5 (https=) | ||
| JP2021512635A5 (https=) | ||
| JP2025023921A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2023123502A5 (https=) | ||
| WO2021008610A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| JP2019525771A5 (https=) | ||
| JP2025142045A5 (https=) | ||
| RU2019126655A (ru) | Нуклеиновые кислоты, кодирующие химерные рецепторы, полипептидные химерные рецепторы, кодируемые ими, векторы экспрессии, содержащие их, выделенные клетки-хозяева, содержащие их, композиции, содержащие выделенные клетки-хозяева, а также способы получения выделенных клеток-хозяев in vitro, способы выбора нуклеиновых кислот, кодирующих химерные рецепторы, in vitro и способы проведения клеточной иммунотерапии у субъекта, имеющего опухоль | |
| JP2021536265A5 (https=) | ||
| JP2018538277A5 (https=) | ||
| JP2018526033A5 (https=) | ||
| JP2022542559A5 (https=) | ||
| JP2015527070A5 (https=) | ||
| JP2020512973A5 (https=) | ||
| JP2019535262A5 (https=) | ||
| CN105194661A (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| CN115066274A (zh) | 三价结合分子 | |
| JP2023502108A5 (https=) | ||
| JP2024510739A5 (https=) | ||
| JP2024504162A5 (https=) | ||
| JP2024536859A5 (https=) |